Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT04389632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04389632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Recruiting
Start date
June 8, 2020
Completion date
March 22, 2029
Enrollment
1,006 (estimated)
Sites
158

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, cutaneous squamous cell cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, exocrine pancreatic adenocarcinoma, gastroesophageal junction adenocarcinoma, her2 negative breast neoplasms, ovarian neoplasms, squamous cell carcinoma of head and neck, stomach neoplasms, urinary bladder neoplasms, uterine cervical neoplasms